Prognostic evaluation of primary biliary cirrhosis and its value in guiding therapeutic regimens

Huang ChunYang; Liu YanMin

doi:10.3969/j.issn.1001-5256.2016.07.009

Issue 7

Jul. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(7): 1266-1272

PDF( 1550 KB)

Prognostic evaluation of primary biliary cirrhosis and its value in guiding therapeutic regimens

DOI: 10.3969/j.issn.1001-5256.2016.07.009

Beijing You An Hospital,Capital Medical University

Research funding:

Received Date: 2016-05-03
Published Date: 2016-07-20

Abstract

Abstract

Prognostic evaluation of patients with primary biliary cirrhosis( PBC) and how to improve the prognosis have attracted much attention. Further therapeutic regimens for PBC patients with poor prognosis has become the direction of clinical and scientific studies. This article summarizes the association between baseline indices and prognosis and prognostic evaluation of patients undergoing ursodeoxycholic acid( UDCA) treatment,introduces the current status of UDCA combined with budesonide,fibrates,and obeticholic acid for patients with poor response to UDCA and the drugs being developed,and analyzes the influencing factors for prognosis and efficacy of UDCA. It is pointed out that prognosis and efficacy should be evaluated before and during UDCA treatment,and that therapeutic regimens should be adjusted in time to improve prognosis.
- liver cirrhosis,
- biliary,
- therapy

FullText(HTML)

References(41)

References

[1]BEUERS U,GERSHWIN ME,GISH RG,et al.Changing nomenclature for PBC:from‘cirrhosis’to‘cholangitis’[J].Gut,2015,64(11):1671-1672.

[2]SHAPIRO JM,SMITH H,SCHAFFNER F.Serum bilirubin:a prognostic factor in primary biliary cirrhosis[J].Gut,1979,20(2):137-140.

[3]ROLL J,BOYER JL,BARRY D,et al.The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis[J].N Engl J Med,1983,308(1):1-7.

[4]CHRISTENSEN E,NEUBERGER J,CROWE J,et al.Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis.Final results of an international trial[J].Gastroenterology,1985,89(5):1084-1091.

[5]DICKSON ER,GRAMBSCH PM,FLEMING TR,et al.Prognosis in primary biliary cirrhosis:model for decision making[J].Hepatology 1989,10(1):1-7.

[6]PRINCE M,CHETWYND A,NEWMAN W,et al.Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis:follow-up for up to 28 years[J].Gastroenterology,2002,123(4):1044-1051.

[7]HEATHCOTE EJ.Management of primary biliary cirrhosis.The American Association for the Study of Liver Diseases practice guidelines[J].Hepatology,2000,31(4):1005-1013.

[8]ANGULO P,LINDOR KD,THERNEAU TM,et al.Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid[J].Liver,1999,19(2):115-121.

[9]CORPECHOT C,ABENAVOLI L,RABAHI N,et al.Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J].Hepatology,2008,48(3):871-877.

[10]CHAN AW,CHAN RC,WONG GL,et al.New simple prognostic score for primary biliary cirrhosis:albumin-bilirubin score[J].JGastroenterol Hepatol,2015,30(9):1391-1396.

[11]JOHNSON PJ,BERHANE S,KAGEBAYASHI C,et al.Assessment of liver function in patients with hepatocellular carcinoma:a new evidence-based approach-the ALBI grade[J].J Clin Oncol,2015,33(6):550-558.

[12]KUMAGI T,GUINDI M,FISCHER SE,et al.Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis[J].Am J Gastroenterol,2010,105(10):2186-2194.

[13]CORPECHOT C,CHAZOUILLRES O,POUPON R.Early primary biliary cirrhosis:biochemical response to treatment and prediction of long-term outcome[J].J Hepatol,2011,55(6):1361-1367.

[14]AZEMOTO N,ABE M,MURATA Y,et al.Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis[J].J Gastroenterol,2009,44(6):630-634.

[15]LAMMERS WJ,van BUUREN HR,HIRSCHFIELD GM,et al.Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis:an international follow-up study[J].Gastroenterology,2014,147(6):1338-1349.

[16]PARS A,CABALLERA L,RODS J.Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid[J].Gastroenterology,2006,130(3):715-720.

[17]KUIPER EM,HANSEN BE,de VRIES RA,et al.Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid[J].Gastroenterology,2009,136(4):1281-1287.

[18]FLOREANI A,CAZZAGON N,MARTINES D,et al.Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis[J].Dig Liver Dis,2011,43(11):887-892.

[19]CORPECHOT C,CARRAT F,POUJOL-ROBERT A,et al.Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis[J].Hepatology,2012,56(1):198-208.

[20]DUAN WJ,ZHANG FK,OU XJ,et al.The clinical profiles of primary biliary cirrhosis with a suboptimal biochemical response to ursodeoxycholic acid[J].Chin J Hepatol,2011,19(2):118-120.(in Chinese)段维佳,张福奎,欧晓娟,等.原发性胆汁性肝硬化患者对熊去氧胆酸应答欠佳的影响因素分析[J].中华肝脏病杂志,2011,19(2):118-120.

[21]CARBONE M,SHARP SJ,FLACK S,et al.The UK-PBC risk scores:derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis[J].Hepatology,2016,63(3):930-950.

[22]LAMMERSWJ,HIRSCHFIELD GM,CORPECHOT C,et al.Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J].Gastroenterology,2015,149(7):1804-1812.

[23]Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association;Chinese Society of Infectious Diseases,Chinese Medical Association.Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J].J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J].临床肝胆病杂志,2015,31(12):1980-1988.

[24]LEUSCHNER M,MAIER KP,SCHLICHTING J,et al.Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis:results of a prospective double-blind trial[J].Gastroenterology,1999,117(4):918-925.

[25]ANGULO P,JORGENSEN RA,KEACH JC,et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid[J].Hepatology,2000,31(2):318-323.

[26]RAUTIAINEN H,KRKKINEN P,KARVONEN AL,et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three-year randomized trial[J].Hepatology,2005,41(4):747-752.

[27]RABAHI N,CHRTIEN Y,GAOUAR F,et al.Triple therapy with ursodeoxycholic acid,budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone[J].Gastroenterol Clin Biol,2010,34(4-5):283-287.

[28]RAUTIAINEN H,KARVONEN AL,KARKKAINEN P,et al.6year follow up of liver histology after budesonide to UDCA combination therapy in PBC compared with UDCA monoterapy[J].J Hepatol,2011,54(Suppl):s517.

[29]RAUTIAINEN H,FRKKILM,NEUVONEN M,et al.Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis[J].Aliment Pharmacol Ther,2006,24(11-12):1545-1552.

[30]NEVENS F,ANDREONE P,MAZZELLA G,et al.The first primary biliary cirrhosis(PBC)phase 3 trial in two decades---an international study of the FXR agonist obeticholic acid[J].J Hepatol,2014,60:s525.

[31]HIRSCHFIELD GM,MASON A,LUKETIC V,et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology,2015,148(4):751-761.

[32]IWASAKI S,OHIRA H,NISHIGUCHI S,et al.The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis:a prospective,multicenter study[J].Hepatol Res,2008,38(6):557-564.

[33]KANDA T,YOKOSUKA O,IMAZEKI F,et al.Bezafibrate treatment:a new medical approach for PBC patients?[J].J Gastroenterol,2003,38(6):573-578.

[34]ITAKURA J,IZUMI N,NISHIMURA Y,et al.Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis[J].Hepatol Res,2004,29(4):216-222.

[35]LEVY C,PETER JA,NELSON DR,et al.Pilot study:fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Aliment Pharmacol Ther,2011,33(2):235-242.

[36]LENS S,LEOZ M,NAZAL L,et al.Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid[J].Liver Int,2014,34(2):197-203.

[37]CORPECHOT C.Primary biliary cirrhosis beyond ursodeoxycholic acid[J].Semin Liver Dis,2016,36(1):15-26.

[38]SUN LM,WANG YP,LIU YM,et al.Differential characteristics ofA-MA-M2 autoantibody in primary biliary cirrhosis and non-PBC patients[J].Chin J Hepatol,2015,23(5):343-349.(in Chinese)孙丽梅,王一鹏,刘燕敏,等.抗线粒体抗体M2亚型在非原发性胆汁性肝硬化患者中的特点[J].中华肝脏病杂志,2015,23(5):343-349.

[39]de LEMOS AS,FOUREAU DM,JACOBS C,et al.Drug-induced liver injury with autoimmune features[J].Semin Liver Dis,2014,34(2):194-204.

[40]LIU YM,LIAO HY,YAN HP,et al.A clinical study of bilirubin rise in short-term in patients with primary biliary cirrhosis[J].Chin J Hepatol,2012,20(8):632-633.(in Chinese)刘燕敏,廖慧钰,闫惠平,等.原发性胆汁性肝硬化患者胆红素短期内上升临床分析[J].中华肝脏病杂志,2012,20(8):632-633.

[41]European Association for the Study of the Liver.EASL clinical practice guidelines:management of cholestatic liver diseases[J].JHepatol,2009,51(2):237-267.

Relative Articles

[1]	Wang Lu, Sun KeShuai, Han ZheYi, Guo ZhangCun, Jia Gui, Gao KeNa, Zhang YaWei, Han Ying. Clinical effect of fenofibrate combined with ursodeoxycholic acid in treatment of primary biliary cholangitis patients with poor response to ursodeoxycholic acid alone[J]. Journal of Clinical Hepatology, 2018, 34(11): 2368-2372. doi: 10.3969/j.issn.1001-5256.2018.11.020
[2]	Lei LiuJie, Tang YingMei. Advances in pharmacotherapy for primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2017, 33(6): 1188-1191. doi: 10.3969/j.issn.1001-5256.2017.06.037
[3]	Chen RongBin, Wu XueMing, Wu Ying, Yao DingKang. Novel therapeutic targets for primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2017, 33(5): 998-1002. doi: 10.3969/j.issn.1001-5256.2017.05.044
[4]	Ni Ping, Fan XiaoLi, Wen MaoYao, Yang Li. New advances in the treatment of refractory primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2017, 33(11): 2230-2234. doi: 10.3969/j.issn.1001-5256.2017.11.040
[5]	Li MengGe, Zhao YaLin, Liu XiaoLi, Wang XinHui, Jiang YuYong, Yang ZhiYun. Effect of different minimally invasive therapies on the prognosis of patients with HBV-related primary liver cancer complicated by portal vein tumor thrombus[J]. Journal of Clinical Hepatology, 2017, 33(4): 684-688. doi: 10.3969/j.issn.1001-5256.2017.04.017
[6]	Zhao DanTong, Yan HuiPing, Liu YanMin, Huang ChunYang, Zhang HaiPing, Zhao Yan, Liao HuiYu. Clinical features and prognosis of patients with primary biliary cholangitis complicated by hepatitis virus infection[J]. Journal of Clinical Hepatology, 2017, 33(8): 1532-1536. doi: 10.3969/j.issn.1001-5256.2017.08.025
[7]	Wang LiFeng, Zhang Ke, Yang Fan, Wang FuSheng. Current status of diagnosis and treatment of primary biliary cholangitis and related challenges in China[J]. Journal of Clinical Hepatology, 2016, 32(10): 1833-1837. doi: 10.3969/j.issn.1001-5256.2016.10.001
[8]	Zhang Wei, ZhuGe YuZheng, Zhang Ming, He QiBin, Zhang Feng, Wang Yi, Zou XiaoPing. Therapeutic effect and safety of transjugular intrahepatic portosystemic shunt in patients with primary biliary cirrhosis and portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(2): 259-263. doi: 10.3969/j.issn.1001-5256.2016.02.012
[9]	Li YanMei, Wang QiXia, Ma Xiong. Research advances in treatment of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1491-1496. doi: 10.3969/j.issn.1001-5256.2016.08.012
[10]	Ning HuiMing, Ou Qiang. Research advances in diagnosis and treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(4): 802-805. doi: 10.3969/j.issn.1001-5256.2016.04.045
[11]	Yang HanZe. Effect of antiviral therapy on long-term prognosis of patients with decompensated hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1104-1107. doi: 10.3969/j.issn.1001-5256.2016.06.016
[12]	Lin Feng. Research advances in clinical diagnosis,prognostic evaluation,and treatment of liver failure[J]. Journal of Clinical Hepatology, 2016, 32(9): 1678-1683. doi: 10.3969/j.issn.1001-5256.2016.09.009
[13]	Yu Yuan, Yang ZongGuo, Chen ChiChi, Lu YunFei, Xu QingNian, Chen XiaoRong. Efficacy of adjuvant therapy with fenofibrate for primary biliary cirrhosis: a Meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1630-1633. doi: 10.3969/j.issn.1001-5256.2015.10.017
[14]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis)(2015)[J]. Journal of Clinical Hepatology, 2015, 31(12): 1980-1988. doi: 10.3969/j.issn.1001-5256.2015.12.004
[15]	Wang Sui, Wang JiangBin. The diagnosis and treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1605-1607. doi: 10.3969/j.issn.1001-5256.2015.10.010
[16]	Wang Qian, Yao DingKang. Research progress in medical treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(5): 462-465. doi: 10.3969/j.issn.1001-5256.2014.05.022
[17]	Zhao DanTong, Liao HuiYu, Liu YanMin, Huang ChunYang, Zhang HaiPing, Sun LiMei, Ma YinXue, Zhao Yan, Yan HuiPing. ROC analysis of prognostic factors in Chinese patients with primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(1): 62-66. doi: 10.3969/j.issn.1001-5256.2014.01.017
[18]	Qin Hua, Bai ShiShan. Advances in treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(9): 719-721. doi: 10.3969/j.issn.1001-5256.2013.09.023
[19]	Liu HongHong, Fu JunLiang, Fu BaoYun, Zhang Zheng, Xu RuoNan, Luo ShengQiang, Shi Ming, Li YongGang, Wang FuSheng. The pathogenesis and risk factors related to prognosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(2): 153-155.
[20]	Zhao YanJuan, Sun ZheYing. The therapeutic effect of ursodeoxycholic acid capsules in patients with primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2010, 26(4): 432-433.

Supplements(0)

Cited By

Cited by

Periodical cited type(6)

1.	李风成，程君，谭林，高学武，王金玲，徐静，李莎莎，姜宁. 肝硬化失代偿期患者早期死亡转归多因素分析. 中外医疗. 2020(09): 14-16 .
2.	王璐璐. KAP理论的健康宣教对原发性胆汁性肝硬化病人治疗依从性及疾病知识认知度的影响. 疾病监测与控制. 2020(03): 216-218 .
3.	陈杰，黄春洋，黄云丽，韩莹，刘燕敏，单晶. 大黄利胆胶囊对熊去氧胆酸经治的原发性胆汁性胆管炎患者的临床观察. 中西医结合肝病杂志. 2020(06): 492-494 .
4.	李沛然，陈霖，刘爱霞，杨丽华，孙杰，陈伟蛟，闫梦迪，郭桐生，李伯安. 原发性胆汁性肝硬化的实验室指标分析. 肝脏. 2018(03): 221-223 .
5.	王芳，郜茜，绽永华，张洪芳. 苯扎贝特联合熊去氧胆酸治疗原发性胆汁性肝硬化的效果及对患者肝功能影响观察. 世界最新医学信息文摘. 2018(A4): 144-145 .
6.	王喜霞. 循证护理模式对原发性胆汁性肝硬化患者术后康复及并发症的影响. 河南医学研究. 2017(07): 1321-1322 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2310) PDF downloads(509)

Prognostic evaluation of primary biliary cirrhosis and its value in guiding therapeutic regimens

DOI: 10.3969/j.issn.1001-5256.2016.07.009